 |
|
Soft Tissue Sarcoma Trial Results
1. Heat Therapy Makes High-Risk Soft Tissue Sarcomas More Treatable
(Posted: 07/09/2007) - Patients with high-risk soft tissue sarcomas whose tumors were treated with a kind of localized heat therapy in addition to receiving other treatment lived longer without their disease worsening or returning, according to findings presented at the 2007 ASCO meeting in Chicago.
2. Imatinib (Gleevec®) Reduces Cancer Recurrence in Patients with Surgically Removed GIST
(Posted: 06/25/2007) - Patients with localized gastrointestinal stromal tumors (GIST) who took imatinib (Gleevec®) after surgical removal of the primary tumor were less likely to have a recurrence of their cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
3. Imatinib 'Treatment Holiday' Risks Disease Progression
(Posted: 04/17/2007) - Patients whose advanced gastrointestinal stromal tumors (GIST) are controlled with the drug imatinib (Gleevec®) risk rapid progression of disease if treatment is interrupted, according to the March 20, 2007, Journal of Clinical Oncology.
4. Gleevec Decreases Cancer Recurrence for Patients with Primary Gastrointestinal Stromal Tumor
(Posted: 04/12/2007) - Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor, a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.
5. Sunitinib Effective Against GIST After Imatinib Fails
(Posted: 08/05/2006) - Patients with gastrointestinal stromal tumors (GIST) for whom the drug imatinib was no longer effective survived four times longer without progressive disease on the drug sunitinib, compared to similar patients taking a placebo, according to findings presented at the 2006 meeting of the American Society of Clinical Oncology. Overall survival was also significantly improved with sunitinib.
1 2 Next >
|
|
|
